{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:03:11Z","timestamp":1790996591150,"version":"4.1.0"},"reference-count":114,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.cpet.2024.09.015","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:08:26Z","timestamp":1731542906000},"page":"89-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical Applications of PET Imaging in Alzheimer\u2019s Disease"],"prefix":"10.1016","volume":"20","author":[{"given":"Shiv","family":"Patil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Ayubcha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Teichner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Subtirelu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia H.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohanad","family":"Ghonim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Ghonim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poul Flemming","family":"H\u00f8ilund-Carlsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abass","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B.","family":"Newberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpet.2024.09.015_bib1","unstructured":"Association as. Alzheimer's disease facts and figures: prevalence. Updated 2024. Available at: https:\/\/www.alz.org\/alzheimers-dementia\/facts-figures#:\u223c:text=An%20estimated%206.9%20million%20Americans,Americans%20with%20Alzheimer's%20are%20women. Accessed September 16, 2024."},{"issue":"2","key":"10.1016\/j.cpet.2024.09.015_bib2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ncl.2017.01.005","article-title":"Early-onset\u00a0alzheimer disease","volume":"35","author":"Mendez","year":"2017","journal-title":"Neurol Clin"},{"issue":"18","key":"10.1016\/j.cpet.2024.09.015_bib3","doi-asserted-by":"crossref","first-page":"488","DOI":"10.15585\/mmwr.mm7218a3","article-title":"Provisional mortality data \u2014 United States, 2022","volume":"72","author":"Ahmad","year":"2023","journal-title":"MMWR Morbidity and Mortality Weekly Report"},{"issue":"Suppl 8","key":"10.1016\/j.cpet.2024.09.015_bib4","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.37765\/ajmc.2020.88482","article-title":"Economic burden of Alzheimer disease and managed care considerations","volume":"26","author":"Wong","year":"2020","journal-title":"Am J Manag Care"},{"issue":"7","key":"10.1016\/j.cpet.2024.09.015_bib5","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.cpet.2024.09.015_bib6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1212\/WNL.38.3.359","article-title":"The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease","volume":"38","author":"Tierney","year":"1988","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.015_bib7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ana.410240110","article-title":"Clinically diagnosed Alzheimer's disease: autopsy results in 150 cases","volume":"24","author":"Joachim","year":"1988","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.cpet.2024.09.015_bib8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","article-title":"Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Jack","year":"2011","journal-title":"Alzheimer's Dementia"},{"issue":"3","key":"10.1016\/j.cpet.2024.09.015_bib9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jalz.2010.03.013","article-title":"Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: genetics core aims, progress, and plans","volume":"6","author":"Saykin","year":"2010","journal-title":"Alzheimer's Dementia"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.015_bib10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40035-022-00315-z","article-title":"A\u00a0review of brain imaging biomarker genomics in Alzheimer\u2019s disease: implementation and perspectives","volume":"11","author":"Li","year":"2022","journal-title":"Transl Neurodegener"},{"issue":"4","key":"10.1016\/j.cpet.2024.09.015_bib11","first-page":"627","article-title":"Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease","volume":"26","author":"Bloudek","year":"2011","journal-title":"J\u00a0Alzheim Dis"},{"issue":"8","key":"10.1016\/j.cpet.2024.09.015_bib12","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimer's Dementia"},{"issue":"4","key":"10.1016\/j.cpet.2024.09.015_bib13","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer's Dementia"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.015_bib14","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12868-018-0465-5","article-title":"Neurovascular dysfunction in vascular dementia, Alzheimer\u2019s and atherosclerosis","volume":"19","author":"Shabir","year":"2018","journal-title":"BMC Neurosci"},{"issue":"10","key":"10.1016\/j.cpet.2024.09.015_bib15","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.tins.2013.07.001","article-title":"Sugar for the brain: the role of glucose in physiological and pathological brain function","volume":"36","author":"Mergenthaler","year":"2013","journal-title":"Trends Neurosci"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.015_bib16","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/snuc.2002.29269","article-title":"Guest editorial: the conception of FDG-PET imaging","volume":"32","author":"Alavi","year":"2002","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.cpet.2024.09.015_bib17","series-title":"Age-associated neurological diseases","first-page":"13","article-title":"Positron emission tomography in the differential diagnosis of organic dementias","author":"Heiss","year":"1991"},{"issue":"suppl 1","key":"10.1016\/j.cpet.2024.09.015_bib18","article-title":"The effect of disease severity on local cerebral glucose metabolism in Alzheimer's disease","volume":"7","author":"Jamieson","year":"1987","journal-title":"J\u00a0Cerebr Blood Flow Metabol"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.015_bib19","first-page":"35","article-title":"High-resolution PET studies in Alzheimer's disease","volume":"4","author":"Kumar","year":"1991","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.cpet.2024.09.015_bib20","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/00004424-199102000-00019","article-title":"Positron emission tomography in neuropsychiatry","volume":"26","author":"Faulstich","year":"1991","journal-title":"Invest Radiol"},{"issue":"4","key":"10.1016\/j.cpet.2024.09.015_bib21","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0001-2998(05)80238-7","article-title":"Single photon tomography in Alzheimer's disease and the dementias","volume":"20","author":"Bonte","year":"1990","journal-title":"Semin Nucl Med"},{"issue":"Suppl I","key":"10.1016\/j.cpet.2024.09.015_bib22","first-page":"168","article-title":"Family history of dementia and regional cerebral glucose utilization in dementia of the Alzheimer type","volume":"39","author":"Friedland","year":"1989","journal-title":"Neurology"},{"key":"10.1016\/j.cpet.2024.09.015_bib23","series-title":"As measured by positron emission tomography","first-page":"231","article-title":"Abnormal brain glucose metabolism in alzheimer\u2019s disease","author":"Rapoport","year":"1991"},{"key":"10.1016\/j.cpet.2024.09.015_bib24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.exger.2017.07.004","article-title":"A\u00a0cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer's disease","volume":"107","author":"Croteau","year":"2018","journal-title":"Exp Gerontol"},{"issue":"7","key":"10.1016\/j.cpet.2024.09.015_bib25","doi-asserted-by":"crossref","first-page":"e68860","DOI":"10.1371\/journal.pone.0068860","article-title":"Glucose metabolism during resting state reveals abnormal brain Networks organization in the alzheimer\u2019s disease and mild cognitive impairment","volume":"8","author":"Sanabria-Diaz","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.cpet.2024.09.015_bib26","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1212\/WNL.50.6.1585","article-title":"Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease","volume":"50","author":"Ibanez","year":"1998","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.cpet.2024.09.015_bib27","first-page":"1238","article-title":"A\u00a0diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface","volume":"36","author":"Minoshima","year":"2020","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2024.09.015_bib28","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2967\/jnumed.107.045385","article-title":"Multicenter standardized 18 F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias","volume":"49","author":"Mosconi","year":"2008","journal-title":"J\u00a0Nucl Med"},{"issue":"6","key":"10.1016\/j.cpet.2024.09.015_bib29","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1007\/s00259-012-2102-3","article-title":"Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET","volume":"39","author":"Ossenkoppele","year":"2012","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.cpet.2024.09.015_bib30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1590\/S1807-59322011001300003","article-title":"Neuroimaging in Alzheimer's disease: current role in clinical practice and potential future applications","volume":"66","author":"Ferreira","year":"2011","journal-title":"Clinics"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.015_bib31","doi-asserted-by":"crossref","first-page":"54","DOI":"10.12779\/dnd.2024.23.1.54","article-title":"The usefulness of 18 F-FDG PET to differentiate subtypes of dementia: the systematic review and meta-analysis","volume":"23","author":"Na","year":"2024","journal-title":"Dementia and Neurocognitive Disorders"},{"issue":"4","key":"10.1016\/j.cpet.2024.09.015_bib32","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1097\/RLU.0000000000002948","article-title":"Longitudinal 18F-FDG images in patients with alzheimer disease over more than 9 Years from a preclinical stage","volume":"45","author":"Ishibashi","year":"2020","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.015_bib33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/brain\/118.1.185","article-title":"Chromosome 14 linked familial Alzheimer's disease","volume":"118","author":"Kennedy","year":"1995","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.cpet.2024.09.015_bib34","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcae159","article-title":"Molecular neuroimaging in dominantly inherited versus sporadic early-onset Alzheimer\u2019s disease","volume":"6","author":"Iaccarino","year":"2024","journal-title":"Brain Communications"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.015_bib35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/jnnp.2003.030882","article-title":"Metabolic interaction between ApoE genotype and onset age in Alzheimer's disease: implications for brain reserve","volume":"76","author":"Mosconi","year":"2005","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"issue":"5","key":"10.1016\/j.cpet.2024.09.015_bib36","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00259-008-1039-z","article-title":"FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer\u2019s disease","volume":"36","author":"Mosconi","year":"2009","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"4","key":"10.1016\/j.cpet.2024.09.015_bib37","first-page":"1197","article-title":"18F-FDG is a superior indicator of cognitive performance compared to 18F-florbetapir in alzheimer\u2019s disease and mild cognitive impairment evaluation: a global quantitative analysis","volume":"70","author":"Khosravi","year":"2019","journal-title":"J\u00a0Alzheim Dis"},{"issue":"12","key":"10.1016\/j.cpet.2024.09.015_bib38","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1212\/01.WNL.0000147469.18313.3B","article-title":"MCI conversion to dementia and the APOE genotype","volume":"63","author":"Mosconi","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.cpet.2024.09.015_bib39","doi-asserted-by":"crossref","first-page":"101771","DOI":"10.1016\/j.nicl.2019.101771","article-title":"Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and 18F-FDG-PET imaging","volume":"22","author":"Ottoy","year":"2019","journal-title":"Neuroimage: Clinical"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.015_bib40","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12883-020-01728-x","article-title":"Predicting MCI progression with FDG-PET and cognitive scores: a longitudinal study","volume":"20","author":"Teng","year":"2020","journal-title":"BMC Neurol"},{"issue":"3","key":"10.1016\/j.cpet.2024.09.015_bib41","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00002093-199601030-00005","article-title":"Positron emission tomography metabolic data corrected for cortical atrophy using magnetic resonance imaging","volume":"10","author":"Labb\u00e9","year":"1996","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"10","key":"10.1016\/j.cpet.2024.09.015_bib42","first-page":"1681","article-title":"Quantitative analysis of PET and MRI data in normal aging and Alzheimer's disease: atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators","volume":"34","author":"Alavi","year":"1993","journal-title":"J\u00a0Nucl Med"},{"issue":"2","key":"10.1016\/j.cpet.2024.09.015_bib43","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00259-019-04519-w","article-title":"Three-year changes of cortical 18F-FDG in amnestic vs. non-amnestic sporadic early-onset Alzheimer\u2019s disease","volume":"47","author":"Vanhoutte","year":"2020","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"6","key":"10.1016\/j.cpet.2024.09.015_bib44","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0969-8051(02)00326-8","article-title":"Benzofuran derivatives as A\u03b2-aggregate-specific imaging agents for Alzheimer\u2019s disease","volume":"29","author":"Ono","year":"2002","journal-title":"Nucl Med Biol"},{"issue":"7","key":"10.1016\/j.cpet.2024.09.015_bib45","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.neurobiolaging.2009.07.002","article-title":"Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI","volume":"32","author":"Landau","year":"2011","journal-title":"Neurobiol Aging"},{"issue":"17","key":"10.1016\/j.cpet.2024.09.015_bib46","doi-asserted-by":"crossref","first-page":"175002","DOI":"10.1088\/1361-6560\/ab35b4","article-title":"Using EQ\u00b7PET to reduce reconstruction-dependent variations in [ 18 F]FDG-PET brain imaging","volume":"64","author":"Vanhoutte","year":"2019","journal-title":"Phys Med Biol"},{"issue":"3","key":"10.1016\/j.cpet.2024.09.015_bib47","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimer's Dementia"},{"issue":"13","key":"10.1016\/j.cpet.2024.09.015_bib48","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1021\/jm030026b","article-title":"Synthesis and evaluation of 11 C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents","volume":"46","author":"Mathis","year":"2003","journal-title":"J\u00a0Med Chem"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.015_bib49","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00019442-200201000-00004","article-title":"Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease","volume":"10","author":"Shoghi-Jadid","year":"2002","journal-title":"Am J Geriatr Psychiatr"},{"issue":"13","key":"10.1016\/j.cpet.2024.09.015_bib50","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2019.2000","article-title":"Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia","volume":"321","author":"Rabinovici","year":"2019","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.cpet.2024.09.015_bib51","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1001\/jama.2015.4669","article-title":"Prevalence of amyloid PET positivity in dementia syndromes","volume":"313","author":"Ossenkoppele","year":"2015","journal-title":"JAMA"},{"issue":"Supplement 1","key":"10.1016\/j.cpet.2024.09.015_bib52","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.2967\/jnumed.121.263195","article-title":"The role of amyloid PET in imaging neurodegenerative disorders: a review","volume":"63","author":"Chapleau","year":"2022","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2024.09.015_bib53","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann Neurol"},{"issue":"18","key":"10.1016\/j.cpet.2024.09.015_bib54","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1002\/hbm.24782","article-title":"Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment","volume":"40","author":"Chandra","year":"2019","journal-title":"Hum Brain Mapp"},{"issue":"8","key":"10.1016\/j.cpet.2024.09.015_bib55","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.neurobiolaging.2010.04.007","article-title":"Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging","volume":"31","author":"Rowe","year":"2010","journal-title":"Neurobiol Aging"},{"issue":"10","key":"10.1016\/j.cpet.2024.09.015_bib56","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00259-013-2478-8","article-title":"[11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment","volume":"40","author":"Br\u00fcck","year":"2013","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"11","key":"10.1016\/j.cpet.2024.09.015_bib57","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2967\/jnumed.109.065284","article-title":"Preclinical properties of 18 F-AV-45: a PET agent for A\u03b2 plaques in the brain","volume":"50","author":"Choi","year":"2009","journal-title":"J\u00a0Nucl Med"},{"issue":"2","key":"10.1016\/j.cpet.2024.09.015_bib58","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1474-4422(08)70001-2","article-title":"Imaging of amyloid \u03b2 in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism","volume":"7","author":"Rowe","year":"2008","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.cpet.2024.09.015_bib59","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1136\/jnnp-2012-302548","article-title":"Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography","volume":"83","author":"Wolk","year":"2012","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"issue":"4","key":"10.1016\/j.cpet.2024.09.015_bib60","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00259-011-2021-8","article-title":"Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment","volume":"39","author":"Camus","year":"2012","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"5S","key":"10.1016\/j.cpet.2024.09.015_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2012.10.007","article-title":"Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging","volume":"9","author":"Johnson","year":"2013","journal-title":"Alzheimer's Dementia"},{"issue":"5","key":"10.1016\/j.cpet.2024.09.015_bib62","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1474-4422(11)70077-1","article-title":"Cerebral amyloid-\u03b2 PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study","volume":"10","author":"Barthel","year":"2011","journal-title":"Lancet Neurol"},{"issue":"19","key":"10.1016\/j.cpet.2024.09.015_bib63","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","article-title":"Prevalence of cerebral amyloid pathology in persons without dementia","volume":"313","author":"Jansen","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.015_bib64","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2850","article-title":"Amyloid-\u03b2 PET in Alzheimer's disease: a systematic review and Bayesian meta-analysis","volume":"13","author":"Ruan","year":"2023","journal-title":"Brain and Behavior"},{"issue":"2","key":"10.1016\/j.cpet.2024.09.015_bib65","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00259-015-3228-x","article-title":"Diagnostic accuracy of 18F amyloid PET tracers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"43","author":"Morris","year":"2016","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"7","key":"10.1016\/j.cpet.2024.09.015_bib66","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.3390\/ijms25073892","article-title":"Alzheimer\u2019s amyloid hypothesis and antibody therapy: melting glaciers?","volume":"25","author":"H\u00f8ilund-Carlsen","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.cpet.2024.09.015_bib67","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jamaneurol.2018.0629","article-title":"Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population-based setting","volume":"75","author":"Roberts","year":"2018","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.015_bib68","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1155\/2009\/609839","article-title":"Amyloid imaging in aging and dementia: testing the amyloid hypothesis in\u00a0vivo","volume":"21","author":"Rabinovici","year":"2009","journal-title":"Behav Neurol"},{"issue":"5","key":"10.1016\/j.cpet.2024.09.015_bib69","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/brain\/awp062","article-title":"Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease","volume":"132","author":"Jack","year":"2009","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.cpet.2024.09.015_bib70","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00259-019-04564-5","article-title":"Suboptimal validity of amyloid imaging-based diagnosis and management of Alzheimer\u2019s disease: why it is time to abandon the approach","volume":"47","author":"Alavi","year":"2020","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"2","key":"10.1016\/j.cpet.2024.09.015_bib71","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00259-011-1960-4","article-title":"Amyloid-\u03b2 imaging with PET in Alzheimer\u2019s disease: is it feasible with current radiotracers and technologies?","volume":"39","author":"Moghbel","year":"2012","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.cpet.2024.09.015_bib72","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejrad.2017.07.014","article-title":"The diagnostic value of FDG and amyloid PET in Alzheimer\u2019s disease\u2014a systematic review","volume":"94","author":"Rice","year":"2017","journal-title":"Eur J Radiol"},{"issue":"25","key":"10.1016\/j.cpet.2024.09.015_bib73","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1056\/NEJMoa054625","article-title":"PET of brain amyloid and tau in mild cognitive impairment","volume":"355","author":"Small","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.cpet.2024.09.015_bib74","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s00259-015-3231-2","article-title":"Tau imaging in neurodegenerative diseases","volume":"43","author":"Dani","year":"2016","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"11","key":"10.1016\/j.cpet.2024.09.015_bib75","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s11910-014-0500-6","article-title":"Tau PET imaging in alzheimer\u2019s disease","volume":"14","author":"Okamura","year":"2014","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"6","key":"10.1016\/j.cpet.2024.09.015_bib76","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/brain\/awu064","article-title":"Non-invasive assessment of Alzheimer\u2019s disease neurofibrillary pathology using 18F-THK5105 PET","volume":"137","author":"Okamura","year":"2014","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.cpet.2024.09.015_bib77","first-page":"457","article-title":"Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807","volume":"34","author":"Chien","year":"2013","journal-title":"J\u00a0Alzheim Dis"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.015_bib78","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13195-022-01048-x","article-title":"Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD subjects\u2014a MissionAD tau sub-study","volume":"14","author":"Bullich","year":"2022","journal-title":"Alzheimer's Res Ther"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.015_bib79","first-page":"232","article-title":"Tau positron emission tomography imaging in tauopathies: the added hurdle of off-target binding","volume":"10","author":"Lemoine","year":"2018","journal-title":"Alzheimer's Dementia: Diagnosis, Assessment & Disease Monitoring"},{"issue":"4","key":"10.1016\/j.cpet.2024.09.015_bib80","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2967\/jnumed.117.197426","article-title":"Correlations of 18 F-THK5351 PET with postmortem burden of tau and astrogliosis in alzheimer disease","volume":"59","author":"Harada","year":"2018","journal-title":"J\u00a0Nucl Med"},{"issue":"S18","key":"10.1016\/j.cpet.2024.09.015_bib81","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1017\/S1092852900014164","article-title":"The interplay of neurotransmitters in Alzheimer's disease","volume":"10","author":"Francis","year":"2005","journal-title":"CNS Spectr"},{"issue":"Supplement 1","key":"10.1016\/j.cpet.2024.09.015_bib82","doi-asserted-by":"crossref","first-page":"33S","DOI":"10.2967\/jnumed.121.263198","article-title":"PET imaging of cholinergic neurotransmission in neurodegenerative disorders","volume":"63","author":"Tiepolt","year":"2022","journal-title":"J\u00a0Nucl Med"},{"issue":"2","key":"10.1016\/j.cpet.2024.09.015_bib83","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.bbr.2010.11.058","article-title":"The cholinergic system in aging and neuronal degeneration","volume":"221","author":"Schliebs","year":"2011","journal-title":"Behav Brain Res"},{"issue":"8","key":"10.1016\/j.cpet.2024.09.015_bib84","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0969-8051(98)00045-6","article-title":"Synthesis of 1-[11c]methylpiperidin-4-yl propionate ([11c]pmp) for in\u00a0vivo measurements of acetylcholinesterase activity","volume":"25","author":"Snyder","year":"1998","journal-title":"Nucl Med Biol"},{"issue":"6","key":"10.1016\/j.cpet.2024.09.015_bib85","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/0969-8051(94)90159-7","article-title":"Design and evaluation of radioactive acetylcholine analogs for mapping brain acetylcholinesterase (AchE) in\u00a0vivo","volume":"21","author":"Irie","year":"1994","journal-title":"Nucl Med Biol"},{"issue":"Supplement","key":"10.1016\/j.cpet.2024.09.015_bib86","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1097\/00002093-200000001-00017","article-title":"Brain acetylcholinesterase activity in alzheimer disease measured by positron emission tomography","volume":"14","author":"Shinotoh","year":"2000","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"4","key":"10.1016\/j.cpet.2024.09.015_bib87","first-page":"1539","article-title":"Voxel-based acetylcholinesterase PET study in early and late onset\u00a0alzheimer\u2019s disease","volume":"62","author":"Hirano","year":"2018","journal-title":"J\u00a0Alzheim Dis"},{"issue":"3","key":"10.1016\/j.cpet.2024.09.015_bib88","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00259-020-05029-w","article-title":"(+)-[18F]Flubatine as a novel \u03b14\u03b22 nicotinic acetylcholine receptor PET ligand\u2014results of the first-in-human brain imaging application in patients with \u03b2-amyloid PET-confirmed Alzheimer\u2019s disease and healthy controls","volume":"48","author":"Tiepolt","year":"2021","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"3","key":"10.1016\/j.cpet.2024.09.015_bib89","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00259-010-1644-5","article-title":"Decreased cerebral \u03b14\u03b22\u2217 nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer\u2019s disease assessed with positron emission tomography","volume":"38","author":"Kendziorra","year":"2011","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.cpet.2024.09.015_bib90","article-title":"The utility of PET imaging in depression","volume":"15doi","author":"Singh","year":"2024","journal-title":"Front Psychiatr"},{"issue":"3","key":"10.1016\/j.cpet.2024.09.015_bib91","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/brain\/116.3.497","article-title":"Loss of brain 5-HT 2 receptors in Alzheimer's disease","volume":"116","author":"Blin","year":"1993","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.cpet.2024.09.015_bib92","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.2967\/jnumed.109.063008","article-title":"Altered brain serotonin transporter and associated glucose metabolism in Alzheimer disease","volume":"50","author":"Ouchi","year":"2009","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2024.09.015_bib93","first-page":"453","article-title":"The reduction of baseline serotonin 2A receptors in mild cognitive impairment is stable at two-year follow-up","volume":"23","author":"Marner","year":"2011","journal-title":"J\u00a0Alzheim Dis"},{"issue":"10","key":"10.1016\/j.cpet.2024.09.015_bib94","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/JGP.0b013e3180488325","article-title":"A\u00a0positron emission tomography study of 5-hydroxytryptamine-1A receptors in alzheimer disease","volume":"15","author":"Lanct\u00f4t","year":"2007","journal-title":"Am J Geriatr Psychiatr"},{"issue":"3","key":"10.1016\/j.cpet.2024.09.015_bib95","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1073\/pnas.0510237103","article-title":"Serotonin 1A receptors in the living brain of Alzheimer's disease patients","volume":"103","author":"Kepe","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.cpet.2024.09.015_bib96","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.neuroimage.2008.01.030","article-title":"A\u00a0distinct [18F]MPPF PET profile in amnestic mild cognitive impairment compared to mild Alzheimer's disease","volume":"40","author":"Truchot","year":"2008","journal-title":"Neuroimage"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.015_bib97","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1460-9568.2003.02716.x","article-title":"Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease","volume":"18","author":"Kemppainen","year":"2003","journal-title":"Eur J Neurosci"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.015_bib98","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1471-2377-14-79","article-title":"PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer\u2019s disease and Lewy body disorders","volume":"14","author":"Siderowf","year":"2014","journal-title":"BMC Neurol"},{"issue":"4","key":"10.1016\/j.cpet.2024.09.015_bib99","first-page":"1603","article-title":"Clinicopathological correlation: dopamine and amyloid PET imaging with neuropathology in three subjects clinically diagnosed with alzheimer\u2019s disease or dementia with Lewy bodies","volume":"80","author":"Gupta","year":"2021","journal-title":"J\u00a0Alzheim Dis"},{"issue":"6","key":"10.1016\/j.cpet.2024.09.015_bib100","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2967\/jnumed.112.112599","article-title":"Assessing mild cognitive impairment with amyloid and dopamine terminal molecular imaging","volume":"54","author":"Albin","year":"2013","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.015_bib101","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12929-023-00976-6","article-title":"Clinical trials of new drugs for Alzheimer disease: a 2020\u20132023 update","volume":"30","author":"Huang","year":"2023","journal-title":"J\u00a0Biomed Sci"},{"issue":"3","key":"10.1016\/j.cpet.2024.09.015_bib102","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/1531-8249(200009)48:3<391::AID-ANA17>3.0.CO;2-H","article-title":"Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex","volume":"48","author":"Kuhl","year":"2000","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.015_bib103","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13195-020-00749-5","article-title":"Change in cognitive function according to cholinesterase inhibitor use and amyloid PET positivity in patients with mild cognitive impairment","volume":"13","author":"Pyun","year":"2021","journal-title":"Alzheimer's Res Ther"},{"key":"10.1016\/j.cpet.2024.09.015_bib104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14283\/jpad.2016.118","article-title":"A\u00a0randomized, double-blind, phase 2 study of the effects of the vaccine vanutide cridificar with qs-21 adjuvant on immunogenicity, safety and amyloid imaging in patients with mild to moderate alzheimer\u2019s disease","author":"Ketter","year":"2016","journal-title":"Journal of Prevention of Alzheimer's Disease"},{"key":"10.1016\/j.cpet.2024.09.015_bib105","doi-asserted-by":"crossref","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early alzheimer\u2019s disease","author":"Budd Haeberlein","year":"2022","journal-title":"Journal of Prevention of Alzheimer's Disease"},{"issue":"4","key":"10.1016\/j.cpet.2024.09.015_bib106","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/alz.12213","article-title":"Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019","volume":"17","author":"Knopman","year":"2021","journal-title":"Alzheimer's Dementia"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.015_bib107","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.cpet.2024.09.015_bib108","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic alzheimer disease","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.015_bib109","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.trci.2019.06.005","article-title":"Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials","volume":"5","author":"Andrews","year":"2019","journal-title":"Alzheimer's Dementia: Translational Research & Clinical Interventions"},{"issue":"2","key":"10.1016\/j.cpet.2024.09.015_bib110","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/alzrt7","article-title":"Persistent treatment with cholinesterase inhibitors and\/or memantine slows clinical progression of Alzheimer disease","volume":"1","author":"Rountree","year":"2009","journal-title":"Alzheimer's Res Ther"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.015_bib111","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/jgs.15069","article-title":"Comparative effectiveness and safety of cognitive enhancers for treating Alzheimer's disease: systematic review and network metaanalysis","volume":"66","author":"Tricco","year":"2018","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"4","key":"10.1016\/j.cpet.2024.09.015_bib112","doi-asserted-by":"crossref","first-page":"e053012","DOI":"10.1136\/bmjopen-2021-053012","article-title":"Comparative safety and efficacy of cognitive enhancers for Alzheimer\u2019s dementia: a systematic review with individual patient data network meta-analysis","volume":"12","author":"Veroniki","year":"2022","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.cpet.2024.09.015_bib113","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMoa2308719","article-title":"Ultrasound blood\u2013brain barrier opening and aducanumab in alzheimer\u2019s disease","volume":"390","author":"Rezai","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.cpet.2024.09.015_bib114","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/MNM.0000000000001723","article-title":"Machine learning in the positron emission tomography imaging of Alzheimer\u2019s disease","volume":"44","author":"Ayubcha","year":"2023","journal-title":"Nucl Med Commun"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859824000865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859824000865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T11:12:09Z","timestamp":1756293129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859824000865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":114,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1556859824000865"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2024.09.015","relation":{},"ISSN":["1556-8598"],"issn-type":[{"value":"1556-8598","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Applications of PET Imaging in Alzheimer\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2024.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}